NCT06466525View on ClinicalTrials.gov

A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease.

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 16, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions

Parkinson Disease

Interventions

DRUG

LBT-3627

Synthetic peptide

DRUG

Placebo

Vehicle

Trial Locations (2)

Unknown

RECRUITING

Alfred Hospital, Melbourne

ACTIVE_NOT_RECRUITING

Nucleus Networks, Melbourne

All Listed Sponsors

lead

Longevity Biotech Australia Pty Ltd (subsidiary)

INDUSTRY

NCT06466525 - A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease. | Biotech Hunter | Biotech Hunter